ALMSAlumis Inc.
What is the market doing?
No clear lean: insiders net buying, but in a downtrend (−66% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −66% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 8, 2026.
Moderately shorted, settled Sep 15, 2026, a few days of normal trading to cover. Up 12% since the previous count, down from 10.1% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ALMS is trading
Alumis Inc. is +72% over the past year while the S&P 500 is +18%: 54 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −66%
vs 200-day average · a clear downtrend
- RSI (14)
- 37
RSI (14) · neutral
- Below its 52-week high
- 76%
Below its 52-week high
Details›
- Last close2026-10-09
- $7.17
- 1 monthS&P 500 +2.7%
- −27%
- 1 yearS&P 500 +18%
- +72%
- vs 50-day average$15.71
- −54%
- 52-week high
- $30.07
- 52-week low
- $3.95
- Annualised volatility
- 123%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $9.2M
| Year | Return |
|---|---|
| 2026 (year to date) | −27% |
| 2025 | +24% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 1 of 2 | +73% |
| Feb | 2 | 1 of 2 | −8.3% |
| Mar | 2 | 1 of 2 | +3.1% |
| Apr | 2 | 1 of 2 | −10% |
| May | 2 | 0 of 2 | −14% |
| Jun | 2 | 1 of 2 | +0.80% |
| Jul | 3 | 2 of 3 | +13% |
| Aug | 3 | 2 of 3 | −1.3% |
| Sep | 3 | 0 of 3 | −32% |
| Oct | 3 | 2 of 3 | +7.4% |
| Nov | 2 | 1 of 2 | +22% |
| Dec | 2 | 1 of 2 | +6.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry